Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy

Affiliated Hospital of Jiangnan University

Status and phase: Enrolling; Early Phase 1

Conditions: Solid Tumor; Breast Cancer Stage II; Breast Cancer Stage III

Treatments: Drug: [18F]SF-DEVD-2; Drug: [18F]-FDG

Study type: Interventional

Funder types: Other

Identifiers

NCT05828238

LS2023012

Details and patient eligibility

About

This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients voluntarily signed informed consent;
2. Age18-70, male or female;
3. Diagnosed with stage 2 or 3 breast cancer
4. Solid tumors、masses larger than 2cm with lymph node metastasis
5. Pathology is HER3+、triple negative patients
6. Patients to be treated with neoadjuvant chemotherapy

Exclusion criteria

1. Age greater than or equal to 70 years old
2. Abnormal liver and kidney function (more than five times the normal value)
3. Diagnosis level of breast cancer stage 4 or second time tumor patients

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

[18F]SF-DEVD-2

Experimental group

Treatment:

Drug: [18F]SF-DEVD-2

Drug: [18F]-FDG